Marine Drugs as a Valuable Source of Natural Biomarkers Used in the Treatment of Alzheimer’s Disease

UMA NATH U1* and DR LAL PRASANTH2

1Department of pharmaceutical chemistry DM Wims college of pharmacy Wayanad
2Department of pharmaceutical Analysis, MGM College of pharmacy, pilathara, Kannur

*Corresponding author: Uma Nath U, Department of pharmaceutical chemistry DM Wims college of pharmacy Wayanad

ABSTRACT

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neuro degeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions.

KEYWORDS: Marine drugs; Alzheimer’s disease; Mechanisms of activity

INTRODUCTION

Right now, 46.8 million persons in the world are suffering from dementia and it is expected that this number will increase to 74.7 million in 2030 and 131.5 million in 2050. Alzheimer’s disease (AD) is the main cause of dementia in the elderly. AD is a progressive, continuous and incurable brain disorder leading to increase severe disability such as memory loss (amnesia), minimal to no communication (aphasia), the inability to perform activitiesofdaily living (ADL) (apraxia), the impairment of the sensory input (development of agnosias). In briefly, AD is a multifactorial neurodegenerative disorder that affects cognition (memory, thinking, and language abilities), quality of life and self-sufficiency in elderly [2]. AD is strictly related to aging, indeed the majority of cases (≥ 90%) are initially diagnosed among persons ≥ 65 years of age (AD with late onset-LOAD). In particular, genes involved in the production of the amyloid β (Aβ) peptides such as amyloid precursor protein (APP), Presenilin 1 (PSEN1), and 2 (PSEN2) may account for as much as 5%–10% of the EOAD incidence.

BRYOSTATIN

Bryostatin 1 is a natural product derived from the marine invertebrate Bugula neritina. It has potent and broad antitumor activity. Bryostatin 1 activates protein kinase C family members, with nanomolar potency for PKCα and ε isotypes.

In the central nervous system, bryostatin 1 activation of PKC boosts synthesis and secretion of the neurotrophic factor BDNF, a synaptic growth factor linked to learning and memory. The compound also activates nonamyloidogenic, α-secretase processing of amyloid precursor protein.

Preclinical work on bryostatin in nervous system diseases has mainly come from the Alkon lab. In their studies, intraperitoneal administration activated brain PKCε and prevented synaptic loss, Aβ accumulation, and memory decline in Alzheimer’s disease transgenic mice. he drugs preserved synapses and improved memory in aged rats, and in rodent models of stroke and Fragile X syndrome. In a different lab, bryostatin given by mouth improved memory and learning in an AD model. In a mouse model of multiple sclerosis, bryostatin promoted anti-inflammatory immune responses and improved neurologic deficits.
MACROALGAE

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are important enzymes involved in the regulation of acetylcholine (ACh) in the cleft of neurons to promote cognitive function. However, loss or rapid degradation of acetylcholine leads to cholinergic dysfunction and synaptic ultimately memory impairment. Hence, cholinesterases have been developed to alleviate cholinergic deficit by restoring ACh levels and improving cognitive function. Seaweed-derived biologically active compounds have been reported to exhibit inhibitory effects on enzymes associated with Alzheimer’s disease. revealed that aqueous-ethanol extracts rich in phlorotannins, phenolic acids, and flavonoids from Ecklonia maxima, Gelidium pristoides, Gracilaria

Citation: UMA NATH U* and DR LAL PRASANTH. Marine Drugs as a Valuable Source of Natural Biomarkers Used in the Treatment of Alzheimer’s Disease. Op Acc J Bio Sci & Res 10(1),2022

DOI: 10.46718/JBGSR.2021.10.000253
Figure 3:

gracilis, and Ulva lactuca exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activities. Furthermore, sulfated polysaccharides obtained from Ulva rigida as well as the aforementioned algal species also showed potent inhibitory effects on BChE and AChE in vitro. Purified fractions of Gelidiella acerosa showed AChE and BChE inhibitory activity. Phytol was identified in the fraction as the most effective constituent. In the same study, molecular docking analysis revealed that phytol tightly binds to the arginine residue at the active site of the enzyme, thereby changing its conformation and exerting its inhibitory effect. AChE inhibitory activity of Codium duthieae, Amphiroa beauvoisii, Gelidium foliaceum, Laurencia complanata, and Rhodomelopsis africana. Hypnea musciformis and Ochtodes secundiramea extracts showed weak inhibitory activity (less than 30% inhibition) on AChE. Jung et al. also reported AChE and BChE inhibitory effects of methanol extracts of Ecklonia cava, Ecklonia kurome, and Myelophycus simplex. Glycoprotein isolated from Undaria pinnatifida showed dose responsive inhibitory effects on butyrylcholinesterase and acetylcholinesterase activities.

MEDITERRANEAN RED SEAWEED HALOPITHYS INCURVA

The close relationship between the amyloid aggregation process and the onset of amyloidosis constantly encourages scientific research in the identification of new natural compounds capable of suppressing the formation of toxic amyloid aggregates. For the first time, our findings demonstrated the in vitro anti-amyloidogenic role of the H. incurva, whose metabolic composition and bioactivity were strongly influenced by seasonality. This work focused on the bioactivity of H. incurva phytocomplex to evaluate the synergistic action of its various constituents, while the structure and functionality of its secondary metabolites will be the subject of further studies.

FASCAPLYSIN

Fascaplysin, a bis-indole alkaloid, was isolated from a marine sponge Fascaplysinopsis Bergquist sp. Fascaplysin is a specific kinase inhibitor for CDK 4.

References:

1. Rengasamy KR, Kulkarni MG, Stirk WA, Van Staden J (2014) Advances in algal drug research with emphasis on enzyme inhibitors. Biotechnol Adv 32: 1364-1381.
2. Hong DD, Hien HT (2008) Nutritional analysis of Vietnamese seaweeds for food and medicine No Title. Biofactors 22: 323-325.
3. Chengkui Z, Tseng C, Junfu Z, Chang CF (1984) Chinese seaweeds in herbal medicine. Hdrobiologia 116: 152-154.
4. Niazi AK, Kalra S, Irfan A, Islam A (2011) Thyroidology over the ages. Indian J Endocrinol Metab 15: S121–S126.
5. Yang Y (2009) Chinese Herbal Medicines: Comparisons and Characteristic: Churchill Livingstone: London, UK Volume 268.

6. Hamed SM, El Rhman AAA, Ibraheem IBM (2018) Role of marine macroalgae in plant protection & improvement for sustainable agriculture technology. Beni-Suef Univ J Basic Appl Sci 7: 104-110.

7. Wells MJ, Potin P, Craigie JS, Raven JA, Merchant SS, et al. (2017) Algae as nutritional and functional food sources: Revisiting our understanding. J Appl Phycol 29: 949-982.

8. Kelman D, Posner EK, Mc Dermid KJ, Tabandera NK, Wright PR, Wright AD (2012) Antioxidant activity of Hawaiian marine algae. Mar Drugs 10: 403-416.

9. Moussavou G, Kwak DH, Obiang Obounou BF, Maranguy CA, Dinzouna Boutamba S, et al. (2014) Anticancer effects of different seaweeds on human colon and breast cancers. Mar Drugs 12: 4898-4911.

10. Riahi CR, Tarhouni S, Kharrat R (2011) Screening of anti-inflammatory and analgesic activities in marine macroalgae from Mediterranean Sea. Arch Inst Pasteur Tunis 88: 19-28.

11. Zhao C, Yang CF, Liu B, Lin L, Sarker SD, et al. (2018) Bioactive compounds from marine macroalgae and their hypoglycemic benefits. Trends Foods Sci Technol 72: 1-12.

12. Tierney MS, Croft AK, Hayes M (2010) A review of anti hypertensive and antioxidant activities in macroalgae. Bot Mar 53: 387-408.

13. Pérez MJ, Falque E, Domingue H (2016) Antimicrobial action of compounds from marine seaweed. Mar Drugs 14: 52.

14. Pangestuti R, Kim SK (2011) Neuroprotective effects of marine algae. Mar Drugs 9: 803-818.

15. Alghazwi M, Kan YQ, Zhang W, Gai WP, Garson MJ, et al. (2016) Neuroprotective activities of natural products from marine macroalgae during 1999-2015. J Appl Phycol 28: 3599-3616.

16. Paris D, Beaulieu Abdelahad D, Bachmeier C, Reed J, Ait Ghezala H, Yakel JL (2017) Cholinergic modulation of the Alzheimer's disease. Oxid Med Cell Longev: 316523.

17. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. J Geriatr Psychiatry Neurol 23: 213-227.

18. Bekris LM, Yu C, Bird TD, Tsuang TW, Wright PR, et al. (2010) Genetics of Alzheimer's disease. J Clin Interv Aging 5: 307-311.

19. Bekris LM, Yu C, Bird TD, Tsuang TW (2010) Genetics of Alzheimer's disease. J Geriatr Psychiatry Neurol 23: 213-227.

20. Alghazwi M, Kan YQ, Zhang W, Gai WP, Garson MJ, et al. (2016) Neuroprotective activities of natural products from marine macroalgae during 1999-2015. J Appl Phycol 28: 3599-3616.

21. Olasehinde TA, Odjadjare EC, Mabinya LV, Olarenwaju AO, Okoh AI, et al. (2019) Chlorella sorokiniiana and Chlorella minuitissima exhibit antioxidant potentials, inhibit cholinesterases and modulate disaggregation of β-amyloid fibrils. Electron J Biotechnol 40: 1-9.

22. Oboh G, Adewunmi TM, Ademosun AO, Olasehinde TA (2016) Sorghum stem extract modulates Na+/K+-ATPase, ecox-5'-nucleotidase, and acetylcholinesterase activities. Comp. Clin Pathol 25: 749-756.

23. Oboh G, Oyeleye SI, Akintemi OA, Olasehinde TA (2018) Moringa oleifera supplemented diet modulates nootropic-related biomolecules in the brain of STZ-induced diabetic rats treated with acarbose. Metab. Brain Dis 33: 457-466.

24. Oboh G, Adewunmi TM, Ademiluyi AO, Olasehinde TA, Ademosun AO, et al. (2018) Phenolic constituents and inhibitory effects of Hibiscus sabdariffa L. Sorrel calyx on cholinergic, monoaminergic, and purinergic enzyme activities. J Diet Suppl 15: 910-922.

25. Oboh G, Ademosun AO, Ogunsuyi OB, Oyedola ET, Olasehinde TA, et al. (2018) In vitro anticholinesterase, antiamonioxide oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida). J Complement Integr Med.

26. Olasehinde TA, Olaranwaju AO, Okoh AI (2019) Aqueous-ethanol extracts of some South African seaweeds inhibit beta-amyloid aggregation, cholinesterases, and beta-secretase activities in vitro. J Food Biochem 43: e12870.

27. Kametani F, Hasegawa M (2018) Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease. Front Neurosci 12: 25.

28. Shal B, Ding W, Ali H, Kim YS, Khan S, et al. (2018) Anti-inflammatory potential of natural products in attenuation of Alzheimer's disease. Front Pharmacol 9: 548.

29. Olasehinde TA, Olaranwaju AO, Okoh AI (2017) Therapeutic potentials of microalgae in the treatment of Alzheimer's disease. Molecules 22: 480.

30. Oboh G, Owuwa EE, Oyeleye SI, Olasehinde TA, Ogunsuyi OB, et al. (2016) In vitro neuroprotective potentials of aqueous and methanol extracts from Heinsia crinita leaves. Food Sci. Hum. Wellness 5: 95-102.

31. Qi C, Kivipelto M, Strauss E (2009) Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11: 111-128.

32. Graham WV, Bonito Oliva A, Sakmar TP (2017) Update on Alzheimer's disease therapy and prevention strategies. Annu Rev Med 68: 413-430.

33. Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 6: 19-33.

34. Frozza RL, Lourenco MV, de Felice FG (2018) Challenges for Alzheimer’s disease therapy: Insights from novel mechanisms beyond memory defects. Front Neurosci 12: 37.

35. Oboh G, Olasehinde TA, Ademosun AO (2014) Essential oil from lemon peels inhibit key enzymes linked to neurodegenerative conditions and pro-oxidant induced lipid peroxidation. J Oleo Sci 63: 373-381.

36. Olasehinde TA, Odjadjare EC, Mabinya LV, Olarenwaju AO, Okoh AI, et al. (2019) Chlorella sorokiniiana and Chlorella minuitissima exhibit antioxidant potentials, inhibit cholinesterases and modulate disaggregation of β-amyloid fibrils. Electron J Biotechnol 40: 1-9.

37. Olasehinde TA, Olaranwaju AO, Ademosun AO, Olasehinde TA (2016) Sorghum stem extract modulates Na+/K+-ATPase, ecox-5'-nucleotidase, and acetylcholinesterase activities. Comp. Clin Pathol 25: 749-756.

38. Oboh G, Oyeleye SI, Akintemi OA, Olasehinde TA (2018) Moringa oleifera supplemented diet modulates nootropic-related biomolecules in the brain of STZ-induced diabetic rats treated with acarbose. Metab. Brain Dis 33: 457-466.

39. Oboh G, Adewunmi TM, Ademiluyi AO, Olasehinde TA, Ademosun AO, et al. (2018) Phenolic constituents and inhibitory effects of Hibiscus sabdariffa L. Sorrel calyx on cholinergic, monoaminergic, and purinergic enzyme activities. J Diet Suppl 15: 910-922.

40. Oboh G, Ademosun AO, Ogunsuyi OB, Oyedola ET, Olasehinde TA, et al. (2018) In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida). J Complement Integr Med.

41. Olasehinde TA, Olaranwaju AO, Okoh AI (2019) Aqueous-ethanol extracts of some South African seaweeds inhibit beta-amyloid aggregation, cholinesterases, and beta-secretase activities in vitro. J Food Biochem 43: e12870.

42. Olasehinde TA, Mabinya LV, Olaranwaju AO, Okoh AI (2019) Characterization of sulfated polysaccharides from Gracilaria gracilis and Ulva lactuca and their radical scavenging, metal chelating, and cholinesterase inhibitory activities. Int J Food Prop 22: 100-110.

43. Olasehinde TA, Mabinya LV, Olaranwaju AO, Okoh AI (2019)
Chemical characterization, antioxidant properties, cholinesterase inhibitory and anti-amyloidogenic activities of sulfated polysaccharides from some seaweeds. Bioact. Carbohydr. Diet Fibre 18: 100182.

44. Syad AN, Rajamohamed BS, Shunmugaiah KP, Devi PK (2016) Neuroprotective effect of the marine macroalgae Gelidiella acerosa: Identification of active compounds through bioactivity-guided fractionation. Pharm. Biol 54: 2073-2081.

45. Rengasamy KR, Amoo SO, Aremu AO, Stirk WA, Gruż J, et al. (2015) Phenolic profiles, antioxidant capacity, and acetylcholinesterase inhibitory activity of eight South African seaweeds. J Appl Phycol 27: 1599-1605.

46. Jung SH, Young UM, Inho K, Suengmok C, Dae Seok H, et al. (2016) in vitro screening for anti-dementia activities of seaweed extracts. J Korean Soc Food Sci Nutr 45, 966-997.

47. Rafiquzzaman SM, Ki EY, Lee JM, Mohibullah M, Badrul Alam M (2015) Anti-Alzheimers and anti-inflammatory activities of a glycoprotein purified from the edible brown alga Undaria pinnatifida. Food Res Int 77: 118-124.

48. Shanmuganathan B, Sheeba MD, Sathya S, Devi PK (2015) Antiaggregation potential of Padina gymnospora against the toxic Alzheimer’s beta-amyloid peptide 25-35 and cholinesterase inhibitory property of its bioactive compounds. PLoS ONE 10: e0141708.

49. Castro Silva ES, Bello M, Hernández Rodríguez M, Correa Basurto J, Murillo Álvarez JI (2018) Rosales-Hernández, M.C.; Muñoz-Ochoa, M. Invitro and insilico evaluation of fucosterol from brown seaweed Cystoseira trinodis (Forsskål) C. Agardh. Arab J Chem 10: S2608-S2614.

50. Cheng X, He P, Lee T, Yao H, Li R, et al. (2014) High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol 184: 141-147.

51. Sathy R, Premkumar P, Karthick C, Moorthi P, Jayachandran KS, et al. (2012) BACE1 in Alzheimer’s disease. Clin Chim Acta 24: 171-178.

52. Rockenstein E, Mante M, Alford M, Adame A, Crews L, et al. (2005) High β-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-β levels. J Biol Chem 280: 32957-32967.

53. Jung HA, Ali MY, Choi R, Jeong HO, Chung HY, et al. (2016) Kinetics and molecular docking studies of fuscofuran and fucosaxanthin, BACE1 inhibitors from brown algae Undaria pinnatifida and Ecklonia stolonifera. Food Chem Toxicol 89: 104-111.

54. Seong SH, Ali MY, Kim KR, Jung HA, Choi JS (2017) BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium. Bioorg Med Chem 25: 3964-3970.

55. Dong X, Wang Y, Qin Z (2009) Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharm Sin 30: 379-387.

56. Wang J, Zheng J, Huang C, Zhao J, Lin J, et al. (2018) Eckmaxol, a phlorotannin extracted from Ecklonia maxima, produces anti-β-amyloid oligomer neuroprotective effects possibly via directly acting on glycogen synthase kinase 3β. ACS Chem Neurosci 9: 1349-1356.

57. Lin JJ, Kang YJ, Shin SA, Bak DH, Lee JW, et al. (2016) Phlorofucofuroeckol A improves glutamate-induced neurotoxicity through modulation of oxidative stress-mediated mitochondrial dysfunction in PC12 cells. PLoS ONE 11: 0163433.

58. Alghazwi M, Smid S, Zhang W (2018) In vitro protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta (Aβ1-42) induced neurotoxicity in PC-12 cells. Neurotoxins 10: 62.

59. Sathya R, Kanaga N, Jeeva S (2017) Antioxidant properties of phlorotannins from brown seaweed Undaria pinnatifida. Food Res Int 77: 118-124.

60. Syad AN, Devi PK (2015) Assessment of anti-amyloidogenic activity of marine red alga G. acerosa against Alzheimer’s beta-amyloid peptide 25-35. Neurrol Res 37: 14-22.

61. Alghazwi M, Smid S, Karpiniec S, Zhang W (2019) Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida. Int J Biol Macromol 121: 207-213.

62. Yang EJ, Ahn S, Ryu J, Choi M, Choi S, et al. (2015) Phloroglucinol attenuates the cognitive deficits of the 5XFAD mouse model of Alzheimer’s disease. PLoS ONE 10: e0135686.

63. Wang J, Zheng J, Huang C, Zhao J, Lin J, et al. (2018) Eckmaxol, a phlorotannin extracted from Ecklonia maxima, produces anti-β-amyloid oligomer neuroprotective effects possibly via directly acting on glycogen synthase kinase 3β. ACS Chem Neurosci 9: 1349-1356.